Enliven Therapeutics Q3 2023 Earnings Report

Reported third quarter financial results and provided a business update.

Key Takeaways

Enliven Therapeutics reported its Q3 2023 financial results, highlighting progress in Phase 1 trials for ELVN-001 and ELVN-002, with initial proof of concept data expected in 2024. The company closed the quarter with $263.5 million in cash, cash equivalents, and marketable securities, expected to provide cash runway into early 2026.

Patient enrollment continues to progress for ELVN-001 and ELVN-002.

Enliven expects to report initial proof of concept data in 2024 for ELVN-001 and ELVN-002.

The Company continues to advance its early-stage pipeline.

As of September 30, 2023, the Company had cash, cash equivalents and marketable securities totaling $263.5 million.

Previous year: -$0.72

-29.2%

Gross Profit

-$79K